-
Something wrong with this record ?
Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetone in vitro
L. Skarydova, M. Nobilis, V. Wsól,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Alcohol Oxidoreductases metabolism MeSH
- Anti-Inflammatory Agents, Non-Steroidal chemistry metabolism MeSH
- Biocatalysis drug effects MeSH
- Biotransformation drug effects MeSH
- Butanones chemistry metabolism MeSH
- Metabolic Detoxication, Phase I * MeSH
- Liver drug effects enzymology MeSH
- Kinetics MeSH
- Humans MeSH
- NADP pharmacology MeSH
- Stereoisomerism MeSH
- Subcellular Fractions drug effects metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
1. Nabumetone is a clinically used non-steroidal anti-inflammatory drug, its biotransformation includes major active metabolite 6-methoxy-2-naphtylacetic acid and another three phase I as well as corresponding phase II metabolites which are regarded as inactive. One important biotransformation pathway is carbonyl reduction, which leads to the phase I metabolite, reduced nabumetone. 2. The aim of this study is the determination of the role of a particular human liver subcellular fraction in the nabumetone reduction and the identification of participating carbonyl reducing enzymes along with their stereospecificities. 3. Both subcellular fractions take part in the carbonyl reduction of nabumetone and the reduction is at least in vitro the main biotransformation pathway. The activities of eight cytosolic carbonyl reducing enzymes--CBR1, CBR3, AKR1B1, AKR1B10, AKR1C1-4--toward nabumetone were tested. Except for CBR3, all tested reductases transform nabumetone to its reduced metabolite. AKR1C4 and AKR1C3 have the highest intrinsic clearances. 4. The stereospecificity of the majority of the tested enzymes is shifted to the production of an (+)-enantiomer of reduced nabumetone; only AKR1C1 and AKR1C4 produce predominantly an (-)-enantiomer. This project provides for the first time evidence that seven specific carbonyl reducing enzymes participate in nabumetone metabolism.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14064253
- 003
- CZ-PrNML
- 005
- 20140708083812.0
- 007
- ta
- 008
- 140704s2013 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3109/00498254.2012.720048 $2 doi
- 035 __
- $a (PubMed)23020786
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Skarydova, Lucie $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Czech Republic.
- 245 10
- $a Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetone in vitro / $c L. Skarydova, M. Nobilis, V. Wsól,
- 520 9_
- $a 1. Nabumetone is a clinically used non-steroidal anti-inflammatory drug, its biotransformation includes major active metabolite 6-methoxy-2-naphtylacetic acid and another three phase I as well as corresponding phase II metabolites which are regarded as inactive. One important biotransformation pathway is carbonyl reduction, which leads to the phase I metabolite, reduced nabumetone. 2. The aim of this study is the determination of the role of a particular human liver subcellular fraction in the nabumetone reduction and the identification of participating carbonyl reducing enzymes along with their stereospecificities. 3. Both subcellular fractions take part in the carbonyl reduction of nabumetone and the reduction is at least in vitro the main biotransformation pathway. The activities of eight cytosolic carbonyl reducing enzymes--CBR1, CBR3, AKR1B1, AKR1B10, AKR1C1-4--toward nabumetone were tested. Except for CBR3, all tested reductases transform nabumetone to its reduced metabolite. AKR1C4 and AKR1C3 have the highest intrinsic clearances. 4. The stereospecificity of the majority of the tested enzymes is shifted to the production of an (+)-enantiomer of reduced nabumetone; only AKR1C1 and AKR1C4 produce predominantly an (-)-enantiomer. This project provides for the first time evidence that seven specific carbonyl reducing enzymes participate in nabumetone metabolism.
- 650 _2
- $a alkoholoxidoreduktasy $x metabolismus $7 D000429
- 650 _2
- $a antiflogistika nesteroidní $x chemie $x metabolismus $7 D000894
- 650 _2
- $a biokatalýza $x účinky léků $7 D055162
- 650 _2
- $a biotransformace $x účinky léků $7 D001711
- 650 _2
- $a butanony $x chemie $x metabolismus $7 D002074
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kinetika $7 D007700
- 650 _2
- $a játra $x účinky léků $x enzymologie $7 D008099
- 650 12
- $a I. fáze biotransformace $7 D050216
- 650 _2
- $a NADP $x farmakologie $7 D009249
- 650 _2
- $a stereoizomerie $7 D013237
- 650 _2
- $a subcelulární frakce $x účinky léků $x metabolismus $7 D013347
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Nobilis, Milan
- 700 1_
- $a Wsól, Vladimir
- 773 0_
- $w MED00004746 $t Xenobiotica; the fate of foreign compounds in biological systems $x 1366-5928 $g Roč. 43, č. 4 (2013), s. 346-54
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23020786 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20140704 $b ABA008
- 991 __
- $a 20140708084102 $b ABA008
- 999 __
- $a ok $b bmc $g 1031737 $s 862985
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 43 $c 4 $d 346-54 $i 1366-5928 $m Xenobiotica $n Xenobiotica $x MED00004746
- LZP __
- $a Pubmed-20140704